Statin-based LFA-1 inhibitor designed at Novartis for use in inflammation, autoimmune diseases July 9, 2001
Takeda describes heterocyclic compounds that inhibit T-cell proliferation and IL-2 production July 3, 2001
Licensing opportunity from NIH: chimeric protein with potential as antiinfective therapeutic June 22, 2001
RSS